Moody Aldrich Partners LLC boosted its holdings in Natera Inc (NASDAQ:NTRA) by 17.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 59,002 shares of the medical research company’s stock after purchasing an additional 8,659 shares during the quarter. Moody Aldrich Partners LLC owned about 0.07% of Natera worth $2,942,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. US Bancorp DE lifted its stake in Natera by 31.8% in the first quarter. US Bancorp DE now owns 1,991 shares of the medical research company’s stock valued at $60,000 after buying an additional 480 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Natera by 285.0% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,925 shares of the medical research company’s stock worth $65,000 after purchasing an additional 1,425 shares during the last quarter. Oppenheimer Asset Management Inc. raised its stake in shares of Natera by 203.2% during the first quarter. Oppenheimer Asset Management Inc. now owns 2,265 shares of the medical research company’s stock worth $68,000 after purchasing an additional 1,518 shares during the last quarter. Advisor Group Holdings Inc. purchased a new stake in shares of Natera during the first quarter worth approximately $68,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Natera by 19.3% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,041 shares of the medical research company’s stock worth $121,000 after acquiring an additional 653 shares in the last quarter. 93.87% of the stock is owned by hedge funds and other institutional investors.
Several research firms have issued reports on NTRA. Piper Sandler reiterated a “buy” rating and issued a $63.00 price objective on shares of Natera in a research report on Monday, June 22nd. JPMorgan Chase & Co. upgraded Natera from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $32.00 to $45.00 in a research report on Thursday, May 7th. Zacks Investment Research cut Natera from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. BidaskClub cut Natera from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 7th. Finally, Cfra cut their price objective on Natera from $39.00 to $36.00 and set a “hold” rating for the company in a research report on Thursday, May 21st. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Natera has a consensus rating of “Buy” and a consensus price target of $46.56.
Shares of Natera stock traded up $0.47 during trading hours on Friday, reaching $48.02. The stock had a trading volume of 579,650 shares, compared to its average volume of 599,588. The firm has a 50 day simple moving average of $46.71 and a two-hundred day simple moving average of $38.70. The firm has a market capitalization of $3.78 billion, a price-to-earnings ratio of -27.92 and a beta of 1.38. The company has a current ratio of 2.81, a quick ratio of 2.73 and a debt-to-equity ratio of 0.38. Natera Inc has a 1 year low of $16.87 and a 1 year high of $51.87.
Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, May 6th. The medical research company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.12. The company had revenue of $94.01 million for the quarter, compared to the consensus estimate of $85.02 million. Natera had a negative return on equity of 78.56% and a negative net margin of 38.28%. The company’s quarterly revenue was up 40.7% compared to the same quarter last year. During the same period last year, the business posted ($0.54) EPS. Sell-side analysts forecast that Natera Inc will post -2.14 EPS for the current year.
In related news, CFO Michael Burkes Brophy sold 1,626 shares of the firm’s stock in a transaction dated Wednesday, July 22nd. The stock was sold at an average price of $49.03, for a total transaction of $79,722.78. Following the sale, the chief financial officer now directly owns 45,771 shares in the company, valued at approximately $2,244,152.13. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gail Boxer Marcus sold 7,278 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $45.99, for a total value of $334,715.22. Following the sale, the director now owns 497 shares in the company, valued at $22,857.03. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 378,555 shares of company stock worth $17,341,128. Company insiders own 9.29% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: Why do companies issue monthly dividends?
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.